Maintenance notice: Some features that submit or update information are temporarily disabled while we migrate the website. You can continue browsing normally. Thank you for your understanding.
A Texas man filed a lawsuit against Bristol-Myers Squibb and AstraZeneca claiming the Type 2 diabetes drug Onglyza (saxagliptin) caused heart failure, according to court documents.
According to Wrendell Chester’s complaint for damages filed on Feb. 1, 2017 in the United States District Court for the Southern District of Texas, he took both Onglyza and Kombiglyze XR (saxagliptin and metformin extended release) between 2010 and 2015. After taking the drugs, he suffered congestive heart failure, heart failure and acute hypoxic respiratory failure — a condition where there is not enough oxygen in the blood.
Improving orthopaedic care, education and research using Internet technologies